Table of Contents

HK J Paediatr (New Series)
Vol 18. No. 2, 2013

HK J Paediatr (New Series) 2013;18:63-68

Original Article

Erythromycin Improves Symptoms and Electrogastrographic Patterns of Children with Dyspepsia

MWY Leung, NSY Chao, KKW Liu


Purpose: Erythromycin is a prokinetic agent which enhances gastric smooth muscle contraction. In this study, we investigate the effect of short term erythromycin on children having dyspepsia symptoms. Methods: Eight children aged 7-18 with persistent dyspeptic symptoms were recruited. They all had abnormal dyspeptic symptom scores and electrogastrographic (EGG) patterns. All children were given erythromycin suspension 2 mg/kg thrice daily for 2 weeks. Results: All 8 children completed the 2-week course of erythromycin. Mean dyspepsia symptom scores before and after treatment were 6.75 and 4.63 respectively (p=0.025). Mean normogastria time in EGG before and after treatment were 65.87% and 77.58% respectively (p=0.012). After erythromycin, these eight children showed a significant difference between pre-prandial and post-prandial dominant power (46.00 dB vs 49.69 dB, p=0.017). None developed drug-related complication. Conclusions: EGG can demonstrate abnormal gastric myoelectrical activity in children having dyspeptic symptoms. Short-term erythromycin significantly improves the symptoms and EGG patterns of these patients.

目的:紅黴素是一種促動劑,能提高胃平滑肌的收縮力。在這項研究中,我們調查短期口服紅黴素對兒童消化不良症狀的影響。方法:共8名7-18歲患有持續性消化不良症狀的兒童。他們的消化不良症狀評分和胃電圖(EGG)模式都出現異常。所有的兒童均給予紅黴素懸浮液2mg/kg體重劑量,每天三次,連續2周。結果:8名兒童完成了 2周的紅黴素療程。治療前後,平均消化不良症狀評分,分別為6.75和4.63(p=0.025)。治療前後,平均EGG 胃電節律時間分別為65.87%和77.58%(p=0.012)。紅黴素療程後,這8名孩子在餐前和餐後的主功率(46.00分貝與49.69分貝,p=0.017)之間出現顯著的差異。沒有與藥物相關的併發症。結論:兒童消化不良症狀的EGG可顯示胃電活動異常。短期紅黴素能明顯改善這情況。

Keyword : Children; Dyspepsia; Electrogastrography; Erythromycin



Functional dyspepsia is a common condition affecting children and adolescents.1 The patients suffer from long history of upper abdominal pain with non-organic causes which are not related to defecation activities.2 Associated symptoms include early satiety, postprandial abdominal distension, nausea, vomiting and anorexia.3,4 The causes of functional dyspepsia are not well known and probably related to gastrointestinal dysmotility.5,6 Gastrointestinal dysmotility is also present in children with gastroesophageal reflux disease (GERD),7 malrotation of gut,8 oesophageal atresia9 and superior mesenteric artery (Wilkie's) syndrome.10 Electrogastrography (EGG) is a noninvasive technique to record and process the gastric myoelectric activity.11 We have shown that abnormal EGG patterns occur more often in children with functional dyspepsia and gastrointestinal motility disorders comparing with controls.12

Erythromycin is a macrolide antibiotic. It is also a motilin agonist which enhances gastric smooth muscle contraction.13 It has been shown that intravenous erythromycin infusion promotes gastric emptying of liquid and solid food.14


Study Design and Subjects

Eight children with age 7 to 18 (mean = 14.1) years old were recruited for the study. The inclusion criteria were (1) children with functional dyspepsia or (2) GERD children with dyspepsia symptoms in spite of esomeprazole treatment. They all had dyspeptic symptoms for more than 6 months and abnormal EGG patterns. Six of them had functional dyspepsia. Preliminary blood and stool investigations were normal. Abdominal ultrasonography was done with normal findings. They had either upper gastrointestinal endoscopy or C13 urea breath test for Helicobacter pylori performed which was normal. Ambulatory 24-hour esophageal pH study was normal. Two children had GERD confirmed by 24-hour esophageal pH study with dyspeptic symptoms and delayed gastric emptying in spite of esomeprazole treatment at a dose of 20 mg daily. The baseline dyspepsia symptom score was assessed in these 8 patients. Six dyspeptic symptoms including upper abdominal discomfort, early satiety, post-prandial abdominal distension, nausea, vomiting and anorexia were described as none (grade 0), mild (grade 1), moderate (grade 2) and severe (grade 3). The total dyspepsia symptom score from 0 to 18 was charted.15

EGG Recordings

All children had baseline EGG performed. They were instructed to fast for 6 hours before the procedure. After skin preparation, four Ag/AgCl skin electrodes were applied to the upper abdominal wall at the gastric fundus, body, antrum and pylorus positions (Figure 1). Two additional electrodes were applied for grounding and reference purposes. After a pre-prandial EGG test for 30 minutes, a standard solid meal at 300 to 450 Kcal was given for 30 minutes. Then post-prandial EGG recording for another 60 minutes was done.16 The raw EGG signals were recorded and amplified by a multi-parametric recorder (Polygraf™ ID, Medtronic) and the data were subjected to customised analysis by the software (Polygram Net®, Medtronic) installed in an IBM-compatible personal computer. The frequency at which the EGG power spectrum had a peak power in the range of 0.5 to 9 cycles per minute (cpm) was defined as EGG dominant frequency. The power at the dominant frequency in the power spectrum was defined as the EGG dominant power. The normal EGG dominant frequency (normogastria) was defined as 2-4 cpm. Bradygastria referred to EGG dominant frequency below 2 cpm, and tachygastria meant EGG dominant frequency more than 4 cpm. Gastric dysrhythmia referred to no identifiable EGG dominant patterns.17 A normal EGG is defined as (i) normal gastric slow wave frequency at 2-4 cpm (normogastria) in over 70% of total recorded time; and (ii) the postprandial dominant power is greater than the pre-prandial one (Figure 2).18

In these eight children with dyspeptic symptoms and abnormal baseline EGG results, erythromycin was given to them as a prokinetic treatment. Erythromycin ethylsuccinate oral suspension (200 mg in 5 ml) was prescribed to them with the dosage of 2 mg/Kg, up to a maximum dose of 100 mg thrice daily. The drug was given 30 minutes before meal. The erythromycin treatment was continued for 2 weeks. After that, they were called back for repeat assessment of dyspepsia symptom score and EGG test. In two patients with GERD, esomeprazole 20 mg daily was given during study period including the baseline and follow-up EGG tests.


The dyspepsia symptom scores and EGG findings before and after erythromycin treatment were compared and analysed by Wilcoxon signed rank test. P value of 0.05 or less was considered to indicate statistical significance. The study was approved by the institutional review board of the hospitals.


All 8 children completed the 2-week course of erythromycin. None of them developed drug-related complication. The dyspepsia symptom score pre-erythromycin treatment ranged from 3 to 11 (mean = 6.75).

Figure 1 Electrogastrography skin electrodes.


Figure 2 Normal electrogastrography.

After erythromycin treatment, six children had improvement of dyspepsia symptom score, one child had no change and one had a worsening score. The mean post-treatment score was 4.63. The difference in dyspepsia symptom score before and after erythromycin was statistically significant (p=0.025) (Table 1).

Table 1 Dyspepsia symptom scores before and after erythromycin treatment
Case Sex Diagnosis Pre-erythromycin symptom score Post-erythromycin symptom score
1 M GERD 8 3
2 F Functional dyspepsia 3 3
3 F Functional dyspepsia 3 1
4 F Functional dyspepsia 8 6
5 F Functional dyspepsia 11 9
6 F Functional dyspepsia 4 5
7 F Functional dyspepsia 8 6
8 F GERD 9 4
Mean symptoms score 6.75 4.63*
*Wilcoxon signed rank test p=0.025
GERD: gastroesophageal reflux disease

In these 8 children before erythromycin treatment, normogastria in EGG ranged from 52.13% to 82.12% of total recorded time (mean = 65.87%). In two children, the normogastria is over 70%. However, the dominant power was abnormal in these 2 children. One of them had post-prandial dominant power smaller than the preprandial one, and one patient had unidentifiable pre-prandial dominant power due to gastric dysrhythmia. Each patient had repeated electrogastrography performed after erythromycin treatment. All patients showed improvement in normogastria percentage. The mean post-treatment EGG normogastria of these children was 77.58%. The difference in EGG normogastria before and after erythromycin treatment was statistically significant (p=0.012) (Table 2).

Table 2 Electrogastrography normogastria before and after erythromycin treatment
Case Sex Diagnosis Pre-erythromycin
normogastria (%)
normogastria (%)
1 M GERD 52.13 71.79
2 F Functional dyspepsia 82.12 89.09
3 F Functional dyspepsia 68.57 80.51
4 F Functional dyspepsia 59.38 73.93
5 F Functional dyspepsia 69.73 70.17
6 F Functional dyspepsia 70.03 78.09
7 F Functional dyspepsia 56.04 71.20
8 F GERD 68.97 85.88
Mean normogastria (%) 65.87 77.58*
*Wilcoxon signed rank test p=0.012
GERD: gastroesophageal reflux disease

Before erythromycin treatment, two children had pre-prandial gastric dysrhythmia such that the EGG dominant power could not be determined. The mean pre-prandial dominant power in the remaining 6 children was 43.80 dB. The mean post-prandial dominant power of these 8 children was 47.49 dB. There was no statistical difference between the pre- and post-prandial EGG dominant power before erythromycin treatment (p=0.25). After erythromycin treatment, the mean pre-prandial dominant power of them was 46.00 dB and the mean post-prandial dominant power was 49.69 dB. There was a statistical significant difference between the pre- and post-prandial EGG dominant power after erythromycin treatment (p=0.017) (Table 3).

Table 3 Electrogastrography dominant power before and after erythromycin treatment
dominant power: (dB)
dominant power: (dB)
Case Pre-prandial Post-prandial Pre-prandial Post-prandial
1 41.2 43.5 41.0 43.5
2 46.2 41.3 42.6 43.8
3 38.8 48.1 46.4 50.3
4 43.5 44.0 47.7 54.4
5 48.0 48.6 46.3 50.1
6 Not defined 57.6 46.8 54.4
7 45.1 49.0 42.9 42.7
8 Not defined 47.8 54.3 58.3
Mean 43.80 47.49 46.00 49.69*
* Wilcoxon signed rank test p=0.017
GERD: gastroesophageal reflux disease


Functional dyspepsia is a common problem in children and adolescents. The symptoms can severely affect the daily activities of the patients and yet all investigations are normal.19 There is some evidence that functional dyspepsia is related to gastrointestinal dysmotility. Some gastrointestinal motility disorder, such as GERD and intestinal malrotation, can present with symptoms similar to functional dyspepsia.

In a previous study, we have shown that abnormal EGG pattern occurred in 58.9% of children with functional dyspepsia, compared with only 12.5% in the control group (p=0.042). Also, children with known gastrointestinal motility disorder had a trend of increased abnormal EGG patterns.12 The results are also compatible with studies by other workers.20-23

Cisapride and metoclopramide are traditional prokinetic agents for treatment of functional dyspepsia and gastrointestinal dysmotility. Use of cisapride has been discouraged because of the potential fatal cardiac complications.24 The efficacy of metoclopramide is conflicting.25,26 Moreover, it can cause extra-pyramidal reactions.27 Erythromycin, being a macrolide antibiotic, is also an agonist of motilin receptor on the antroduodenum which enhances enteric smooth muscle contractions. Numerous reports have supported the safety and efficacy of erythromycin as a prokinetic in neonates and infants.28,29 In the present study, we have shown that short term oral erythromycin suspension is a safe and well-tolerated prokinetic agent to be used in children with functional dyspepsia and GERD. All children completed the two-week treatment without side effects. The prokinetic dosage (6 mg/Kg/day) we used is smaller than the antibiotic dosage (30-50 mg/Kg/day). We believe a low dose regime should be used, because some side effects of erythromycin, such as gastrointestinal disturbance, may be dose dependent.30

The dyspepsia symptom scores were improved in 6 out of 8 children (75.0%) after taking erythromycin for two weeks. However, the degree of improvement in symptoms was different and there was no improvement in two children (Table 1). There may be multiple causes for the different responses to erythromycin. Firstly, the symptom score is a clinical assessment by the patients themselves, which involved subjective variability. Also, erythromycin may relieve some dyspepsia symptoms (such as post-prandial abdominal distension) to a more extent than others. Moreover, it is not certain whether two-week treatment of erythromycin is adequate, or a longer period is necessary.

There are only few studies on electrogastrographic changes on children after erythromycin treatment.31 It has been shown that 4-week treatment of cisapride improved the post-prandial EGG dominant frequency in adult with non-ulcer dyspepsia.32 In our study, the EGG dominant frequency improved in all 8 children after erythromycin treatment. The mean normogastria improved from 65.87% to 77.58%. Erythromycin not only regulates the EGG dominant frequency, but also improves the EGG dominant power. It seems to enhance both pre-prandial and post-prandial EGG dominant power, though not statistically significant. The stronger gastric myoelectric activity after meal may be related to stronger antral smooth muscle contraction and subsequently better gastric emptying.33 It was reported that acceleration of gastric emptying occurred after intravenous erythromycin infusion in healthy adults.34

Dyspepsia is a heterogeneous condition. Gastric dysmotility is only one of the possible causes. The exact relation of gastric dysmotility to dyspepsia symptoms is not clear. In some patients, improvement of EGG patterns may not correlated well with relieve of dyspepsia symptoms.

We admit that the sample size was small in this study. Moreover, the dyspepsia symptom score reported by the patients may be subjective and due to the placebo effect. In future, a larger scale prospective randomised controlled study should be performed.

In conclusion, short term low dose oral erythromycin suspension significantly improves the symptoms and electrogastrographic patterns of children with functional dyspepsia and gastroesophageal reflux disease. Electrogastrography, a non-invasive armamentarium, is useful in monitoring the progress of treatment. Further studies are indicated to investigate different dosages, durations and long term results of erythromycin treatment on children with functional dyspepsia and gastrointestinal motility disorders.


1. Chitkara DK, Rawat DJ, Taley NJ. The epidemiology of childhood recurrent abdominal pain in Western Countries: A systemic review. Am J Gastroenterol 2005;100:1868-75.

2. Caplan A, Walker L, Rasquin A. Validation of the Pediatric Rome II criteria for functional gastrointestinal disorders using the questionnaire on pediatric gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;41:305-16.

3. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological profiles, treatment and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998;43:2398-404.

4. Jebbink HJ, Smout AJ, van Berge-Henegouwen GP. Pathophysiology and treatment of functional dyspepsia. Scand J Gastroenterol Suppl 1993;200:8-14.

5. Kerlin P. Postprandial antral hypomotility in patients with idiopathic nausea and vomiting. Gut 1989;30:54-9.

6. Stanghellini V, Ghidini C, Maccarini MR, Paparo GF, Corinaldesi R, Barbara L. Fasting and postprandial gastrointestinal motility in ulcer and non-ulcer dyspepsia. Gut 1992;33:184-90.

7. Sifrim D, Zerbib F. Gastroesophageal reflux disease. Curr Opin Gastroenterol 2002;18: 447-53.

8. Devane SP, Coombes R, Smith VV, et al. Persistent gastrointestinal symptoms after correction of malrotation. Arch Dis Child 1992;67:218-21.

9. Bokay J, Kis E, Verebelv T. Myoelectrical activity of the stomach after surgical correction of esophageal atresia. J Pediatr Surg 2005;40:1732-6.

10. Martin RJ, Khor TS, Vermeulen T, Hall J. Wilkie's syndrome may be due to poor motility. ANZ J Surg 2005;75:1027.

11. Simonian HP, Panganamamula K, Parkman HP, et al. Multichannel EGG in normal subjects: a multicenter study. Dig Dis Sci 2004;49:595-601.

12. Leung MW, Wong BP, Chao NS, Chung KW, Kwok WK, Liu KK. Electrogastrography (EGG) in the management of pediatric functional dyspepsia & motility disorder. J Pediatr Surg 2006;41:2069-72.

13. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 1989;257:G470-4.

14. Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54:455-60.

15. Parkman HP, Miller MA, Trate D, et al. Electrogastrography and gastric emptying scintigraphy are complementary for assessment of dyspepsia. J Clin Gastroenterol 1997;24:214-9.

16. Levanon D, Chen JZ. Electrogastrography: Its role in managing gastric disorders. J Pediatr Gastroenterol Nutr 1998;27:431-3.

17. Chang FY. Electrogastrography: basic knowledge, recording, processing and its clinical applications. J Gastroenterol Hepatol 2005;20:502-16.

18. Friesen CA, Lin Z, Hyman PE, et al. Electrogastrography in pediatric functional dyspepsia: relationship to gastric emptying and symptom severity. J Pediatr Gastroenterol Nutr 2006;42:265-9.

19. Babara L, Camilleri M, Corinaldesi R, et al. The definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci 1989;34:1272-6.

20. Lin Z, Eaker EY, Sarosiek I, McCallum RW. Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol 1999;94:2384-9.

21. Leahy A, Besherdas K, Clayman C, Mason I, Epstein O. Abnormalities of the electrogastrogram in functional gastrointestinal disorders. Am J Gastroenterol 1999;94:1023-8.

22. Pytrus T, Iwanczak B, Iwanczak V. Gastric electrical activity in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2004;39(Suppl 1):S444.

23. Friesen C, Lin Z, Garola R, et al. Chronic gastritis is not associated with gastric dysrhythmia or delayed solid emptying in children with dyspepsia. Dig Dis Sci 2005;50:1012-8.

24. Tonini M, De Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999;13:1585-91.

25. Tolia V, Calhoun J, Kuhns L, Kauffman RE. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J Pediatr 1989;115:141-5.

26. Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr 1986;5:556-9.

27. Putnam PE, Orenstein SR, Wessel HB, et al. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr 1992;121:983-5.

28. Costalos C, Gounaris A, Varhalama E, et al. Erythromycin as a prokinetic agent in preterm infants. J Pediatr Gastroenterol Nutr 2002;34:23-5.

29. Ng PC, So KW, Fung KS, et al. Randomized controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants. Arch Dis Child Fetal Neonatal Ed 2001;84:F177-182.

30. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993;105:1886-99.

31. Faure C, Wolff VP, Navarro J. Effect of meal and intravenous erythromycin on manometric and electrogastrographic measurements of gastric motor and electrical activity. Dig Dis Sci 2000;45:525-8.

32. Besherdas K, Leahy A, Mason I, Harbord M, Epstein O. The effect of cisapride on dyspepsia symptoms and the electrogastrogram in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1998;12:755-9.

33. Chen JD, Lin ZY, Edmunds MC 3rd, McCallum RW. Effects of octreotide and erythromycin on gastric myoelectrical and motor activities in patients with gastroparesis. Dig Dis Sci 1998;43:80-9.

34. DiBaise JK, Park FL, Lyden E, Brand RE, Brand RM. Effects of low doses of erythromycin on the 13C Spirulina platensis gastric emptying breath test and electrogastrogram: a controlled study in healthy volunteers. Am J Gastroenterol 2001;96:2041-5.


This web site is sponsored by Johnson & Johnson (HK) Ltd.
©2022 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.